|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS
|
|
|
|
 |
|
|
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer
|
Oliver Sartor, MD and Michael Morris, MD
Oliver Sartor and Michael Morris join Charles Ryan to discuss Lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial.
|
|
|
|
|
|
|
|
|
 |
|
|
The Use of Novel Imaging Methods in the Prostate Cancer
|
Stefano Fanti, MD
Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care.
|
|
|
|
|
|
|
|
|
 |
|
|
Incorporate Next Generation Imaging Tools Into Clinical Practice
|
Piet Ost, MD, PhD
Piet Ost shares details of his EAU 2019 presentation focusing on biochemical recurrent prostate cancer, specifically in the recurrent setting, and answering the question such as should we be investing in this novel imaging for all patients or should we dial back a bit and only have that for selected patients? Who should get this imaging?
|
|
|
|
|
|
|
|
|
 |
|
|
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy
|
Misha Beltran, MD
Misha Beltran shares details on the Department of Defense grant, a collaboration with Scott Tagawa and Neil Bander at Weill Cornell, and now a continuing effort at the Dana-Farber Cancer Institute. This grant is providing funding to really hone in on the therapeutic side of who are the patients most likely to benefit from PSMA scanning.
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
| Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging |
| Ian Davis, MB, BS, PhD, FRACP, FAChPM |
| As a follow-up to Dr. Stefano Fanti’s presentation on the advantages of PSMA PET-CT imaging, Dr. Ian Davis from Melbourne discussed some of the pitfalls and disadvantages of PSMA PET-CT in advanced prostate cancer imaging. |
|
|
|
|
|
|
|
|
|
| PSMA Targeted Therapies
|
| Michael Hofman, MBBS (Hons), FRACP, FAANMS
|
| Professor Michael Hofman presented on prostate-specific membrane antigen (PSMA) targeted therapies during the Management of castration-resistant prostate cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019.
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
| Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer
|
| Michael Hofman, MBBS (Hons), FRACP, FAANMS,
|
| Professor Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically.
|
|
|
|
|
|
|
|
|
|
